Your browser doesn't support javascript.
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
Yamamoto, Shohei; Fukunaga, Ami; Tanaka, Akihito; Takeuchi, Junko S; Inoue, Yosuke; Kimura, Moto; Maeda, Kenji; Ueda, Gohzoh; Mizoue, Tetsuya; Ujiie, Mugen; Sugiura, Wataru; Ohmagari, Norio.
  • Yamamoto S; Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Fukunaga A; Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tanaka A; Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Takeuchi JS; Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Inoue Y; Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kimura M; Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Maeda K; Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ueda G; Division of Core Diagnostics, Abbott Japan LLC, Tokyo, Japan.
  • Mizoue T; Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: mizoue@hosp.ncgm.go.jp.
  • Ujiie M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sugiura W; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Vaccine ; 40(13): 1924-1927, 2022 03 18.
Article in English | MEDLINE | ID: covidwho-1757911
ABSTRACT
High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2022 Document Type: Article Affiliation country: J.vaccine.2022.02.052

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2022 Document Type: Article Affiliation country: J.vaccine.2022.02.052